Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CytoMed Therapeutics Limited - Ordinary Shares (NQ:GDTC)

2.220 -0.080 (-3.47%)
Streaming Delayed Price Updated: 3:38 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,392
Open 2.260
Bid (Size) 2.170 (5)
Ask (Size) 2.400 (2)
Prev. Close 2.300
Today's Range 2.210 - 2.290
52wk Range 1.200 - 4.050
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire

Performance

YTD
-36.6%
-36.6%
1 Month
-19.0%
-19.0%
3 Month
-21.0%
-21.0%
6 Month
-3.9%
-3.9%
1 Year
+4.6%
+4.6%

More News

Read More
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor
Via Benzinga
CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Navigating the Challenges Facing an Aging Global Population: How CytoMed Seeks to Help Boost Cartilage Regeneration
Via Spotlight Growth
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration
Via ACCESSWIRE
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
US Stocks Gain; Uber Posts Upbeat Sales
Via Benzinga
Topics Stocks
Exposures US Equities
Why Container Store Group Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga

Frequently Asked Questions

Is CytoMed Therapeutics Limited - Ordinary Shares publicly traded?
Yes, CytoMed Therapeutics Limited - Ordinary Shares is publicly traded.
What exchange does CytoMed Therapeutics Limited - Ordinary Shares trade on?
CytoMed Therapeutics Limited - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for CytoMed Therapeutics Limited - Ordinary Shares?
The ticker symbol for CytoMed Therapeutics Limited - Ordinary Shares is GDTC on the Nasdaq Stock Market
What is the current price of CytoMed Therapeutics Limited - Ordinary Shares?
The current price of CytoMed Therapeutics Limited - Ordinary Shares is 2.220
When was CytoMed Therapeutics Limited - Ordinary Shares last traded?
The last trade of CytoMed Therapeutics Limited - Ordinary Shares was at 05/09/25 03:38 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.